Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc.

District Court, W.D. Texas·Decided November 28, 2022·No. 1:20-cv-00783·Unknown

Opinion

UNITED STATES DISTRICT COURT WESTERN DISTRICT OF TEXAS AUSTIN DIVISION

HOMELAND INSURANCE § COMPANY OF NEW YORK, § Plaintiff § § v. § CIVIL NO. 1-20-CV-783-RP

§ CLINICAL PATHOLOGY § LABORATORIES, INC., § Defendant

ORDER

Now before the Court are Homeland Insurance Company of New York’s Motions to Compel filed October 3, 2022 (Dkt. 151; Dkt. 152); Defendant’s Opposed Motion for Leave to File a One- Page Sur-Reply to Plaintiff’s Reply in Support of its Motions to Compel, filed October 24, 2022 (Dkt. 162); and the associated response and reply briefs. By Text Order entered October 26, 2022, the District Court referred the motions to the undersigned Magistrate Judge for disposition, pursuant to 28 U.S.C. § 636(b)(1)(A), Federal Rule of Civil Procedure 72, and Rule 1(c) of Appendix C of the Local Rules of the United States District Court for the Western District of Texas (“Local Rules”).1 The Court held a hearing on the Motions to Compel on November 14, 2022. I. Background Homeland Insurance Company of New York (“Homeland”) brings this insurance coverage lawsuit against Clinical Pathology Laboratories, Inc. (“CPL”) and CPL’s parent company, Sonic Healthcare USA, Inc. (“Sonic USA”) (collectively, “Defendants”). Homeland seeks a declaration that it has no duty to reimburse Defendants for defending medical negligence lawsuits filed against

1 Defendant’s Motion and many of the related filings are sealed. In this Order, the Court cites redacted versions of the relevant filings and quotes no sealed documents. them in Ireland relating to allegedly misread pap smear slides used in cervical cancer screening. Homeland’s Second Amended Complaint, Dkt. 56. Homeland also brings claims for breach of warranty, reformation, and promissory estoppel. Id. CPL asserts several counterclaims against Homeland, including breach of contract, anticipatory breach of contract, violations of the Texas Insurance Code, and a claim for attorneys’ fees. CPL’s First Amended Counterclaim, Dkt. 46.

In the instant Motions to Compel, Homeland asks the Court to compel CPL to produce certain documents that CPL has withheld based on the attorney-client privilege and work product doctrine. II. Legal Standards Under Federal Rule of Civil Procedure 26(b)(1), parties “may obtain discovery regarding any nonprivileged matter that is relevant to any party’s claim or defense and proportional to the needs of the case.” Generally, the scope of discovery is broad. Crosby v. La. Health Serv. & Indem. Co., 647 F.3d 258, 262 (5th Cir. 2011). “A discovery request is relevant when the request seeks admissible evidence or ‘is reasonably calculated to lead to the discovery of admissible evidence.’” Id. (quoting Wiwa v. Royal Dutch Petrol. Co., 392 F.3d 812, 820 (5th Cir. 2004)). After a party has attempted in good faith to obtain discovery without court action, that party

may move for an order compelling disclosure or discovery. FED. R. CIV. P. 37(a)(1). “The Court must balance the need for discovery by the requesting party and the relevance of the discovery to the case against the harm, prejudice, or burden to the other party.” Cmedia, LLC v. LifeKey Healthcare, LLC, 216 F.R.D. 387, 389 (N.D. Tex. 2003). A trial court “enjoys wide discretion in determining the scope and effect of discovery.” Equal Emp. Opportunity Comm’n v. BDO USA, L.L.P., 876 F.3d 690, 698 (5th Cir. 2017) (citation omitted). “The scope of discovery in civil cases under Federal Rule of Civil Procedure 26(b)(1) does not include privileged information or, absent the showing that Federal Rule of Civil Procedure 26(b)(3) mandates, work product protected information.” Jolivet v. Compass Grp. USA, Inc., 340 F.R.D. 7, 17 (N.D. Tex. 2021) (internal citation and quotations omitted). In diversity cases such as this, state law applies to claims of attorney-client privilege, while federal law governs whether the items are immune from discovery under the work product doctrine. FED. R. EVID. 501; In re Avantel, S.A., 343 F.3d 311, 323 (5th Cir. 2003); Dunn v. State Farm Fire & Cas. Co., 927 F.2d 869, 875 (5th Cir. 1991); White Lodging Servs. Corp. v. Liberty Mut. Fire Ins. Co., No. A-17-CA-

277-SS, 2019 WL 13080133, at *2 n.2 (W.D. Tex. Mar. 19, 2019). Therefore, application of the attorney-client privilege is determined by Texas law, while federal common law governs the work product privilege. The attorney-client privilege “is the oldest of the privileges for confidential communications known to the common law.” Upjohn Co. v. United States, 449 U.S. 383, 389 (1981). “The privilege promotes free discourse between attorney and client, thereby advancing the effective administration of justice.” In re Nat’l Lloyds Ins. Co., 532 S.W.3d 794, 803 (Tex. 2017). “Pleading and producing evidence establishing the existence of a privilege is the burden of the party seeking to avoid discovery. The party asserting the privilege must establish by testimony or affidavit a

prima facie case for the privilege.” In re Mem’l Hermann Hosp. Sys., 464 S.W.3d 686, 698 (Tex. 2015). The work product doctrine is distinct from and broader than the attorney-client privilege. United States v. Nobles, 422 U.S. 225, 238 n.11 (1975). The work product doctrine “insulates a lawyer’s research, analysis of legal theories, mental impressions, notes, and memoranda of witnesses’ statements from an opposing counsel’s inquiries.” Dunn, 927 F.2d at 875. “It protects materials prepared in anticipation of litigation, whether those materials were prepared by the attorney or by agents of the attorney.” Adams v. Mem’l Hermann, 973 F.3d 343, 349 (5th Cir. 2020). A party asserting a privilege exemption from discovery bears the burden of demonstrating its applicability. In re Santa Fe Int’l Corp., 272 F.3d 705, 710 (5th Cir. 2001). A party claiming a privilege must “(i) expressly make the claim; and (ii) describe the nature of the documents, communications, or tangible things not produced or disclosed—and do so in a manner that, without revealing information itself privileged or protected, will enable other parties to assess the claim.”

Free access — add to your briefcase to read the full text and ask questions with AI

Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc., (W.D. Tex. 2022).

Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc. (Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

In Re Santa Fe International Corp.
272 F.3d 705 (Fifth Circuit, 2001)
In Re: Avantel, S.A.
343 F.3d 311 (Fifth Circuit, 2003)
United States v. Nobles
422 U.S. 225 (Supreme Court, 1975)
Upjohn Co. v. United States
449 U.S. 383 (Supreme Court, 1981)
Crosby v. Louisiana Health Service and Indem. Co.
647 F.3d 258 (Fifth Circuit, 2011)
In Re EI DuPont De Nemours and Co.
136 S.W.3d 218 (Texas Supreme Court, 2004)
In Re Living Centers of Texas, Inc.
175 S.W.3d 253 (Texas Supreme Court, 2005)
Exxon Corp. v. St. Paul Fire & Marine Insurance
903 F. Supp. 1007 (E.D. Louisiana, 1995)
Republic Insurance Co. v. Davis
856 S.W.2d 158 (Texas Supreme Court, 1993)
Warrior Energy Services Corp. v. ATP Titan M/V
551 F. App'x 749 (Fifth Circuit, 2014)
Ken Paxton, Attorney General of Texas v. City of Dallas
509 S.W.3d 247 (Texas Supreme Court, 2017)
in Re Stephens Inc.
579 S.W.3d 438 (Court of Appeals of Texas, 2019)
Delise Adams v. Memorial Hermann
973 F.3d 343 (Fifth Circuit, 2020)
In re XL Specialty Insurance Co.
373 S.W.3d 46 (Texas Supreme Court, 2012)
Cmedia, LLC v. LifeKey Healthcare, LLC
216 F.R.D. 387 (N.D. Texas, 2003)